IL197633A - A combination of mva and taxane for the treatment of cancer with overexpression of her – 2 - Google Patents
A combination of mva and taxane for the treatment of cancer with overexpression of her – 2Info
- Publication number
- IL197633A IL197633A IL197633A IL19763309A IL197633A IL 197633 A IL197633 A IL 197633A IL 197633 A IL197633 A IL 197633A IL 19763309 A IL19763309 A IL 19763309A IL 197633 A IL197633 A IL 197633A
- Authority
- IL
- Israel
- Prior art keywords
- taxane
- mva
- treatment
- combination
- expressing cancer
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940123237 Taxane Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85003106P | 2006-10-06 | 2006-10-06 | |
| PCT/US2007/021436 WO2008045346A2 (en) | 2006-10-06 | 2007-10-05 | Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL197633A0 IL197633A0 (en) | 2011-08-01 |
| IL197633A true IL197633A (en) | 2017-03-30 |
Family
ID=39283388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL197633A IL197633A (en) | 2006-10-06 | 2009-03-17 | A combination of mva and taxane for the treatment of cancer with overexpression of her – 2 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7807146B2 (OSRAM) |
| EP (2) | EP2596801B1 (OSRAM) |
| JP (2) | JP5964540B2 (OSRAM) |
| AU (1) | AU2007307080B2 (OSRAM) |
| CA (1) | CA2665068C (OSRAM) |
| DK (2) | DK2596801T3 (OSRAM) |
| ES (1) | ES2500465T3 (OSRAM) |
| IL (1) | IL197633A (OSRAM) |
| NZ (2) | NZ575388A (OSRAM) |
| PT (1) | PT2073837E (OSRAM) |
| WO (1) | WO2008045346A2 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230198B1 (hu) * | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| NZ575388A (en) * | 2006-10-06 | 2012-03-30 | Bn Immunotherapeutics Inc | Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer |
| US20110206736A1 (en) * | 2008-09-23 | 2011-08-25 | Thomas Jefferson University | Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same |
| CN103370914B (zh) * | 2010-11-02 | 2018-12-21 | 瑞典爱立信有限公司 | 用于媒体描述输送的方法和装置 |
| US9463238B2 (en) | 2011-12-09 | 2016-10-11 | Bavarian Nordic A/S | Recombinant poxvirus vector comprising tetanus toxin fragment C |
| EP2788021B1 (en) | 2011-12-09 | 2017-01-18 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| EP2908851A1 (en) * | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| CN105379295A (zh) | 2013-07-03 | 2016-03-02 | 皇家Kpn公司 | 分段内容的流送 |
| JP6788500B2 (ja) | 2013-10-23 | 2020-11-25 | アメリカ合衆国 | Ｍｕｃ１−ｃ癌タンパク質のｈｌａ−ａ２４アゴニストエピトープ及び組成物及び使用方法 |
| JP2018510143A (ja) | 2015-02-25 | 2018-04-12 | メモリアル スローン ケタリング キャンサー センター | 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用 |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| BR112018016948A2 (pt) | 2016-02-25 | 2019-01-08 | Memorial Sloan Kettering Cancer Center | mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos |
| EP3419648A4 (en) | 2016-02-25 | 2019-09-11 | Memorial Sloan-Kettering Cancer Center | REPLICATING COMPETENTES WEAKENED VACCINIA VIRUSES WITH DELETION OF THYMIDINE KINASE WITH AND WITHOUT EXPRESSION OF HUMAN FLT3L OR GM-CSF FOR CANCER IMMUNOTHERAPY |
| US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| US11306292B2 (en) | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3706768A4 (en) * | 2017-11-06 | 2021-08-25 | Memorial Sloan Kettering Cancer Center | USE OF THE HEAT-INACTIVATED VACCINE VIRUS AS A VACCINE IMMUNE ADJUDENT |
| US12252702B2 (en) | 2018-09-15 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| PH12022551208A1 (en) | 2019-11-18 | 2023-04-24 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| DK0735893T3 (da) | 1993-09-14 | 2009-03-09 | Pharmexa Inc | PAN DR-bindende peptider til styrkelse af immunsvaret |
| US6326356B1 (en) * | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| DE19729279A1 (de) | 1997-07-09 | 1999-01-14 | Peter Hildebrandt | Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt |
| DE69918146T2 (de) | 1998-10-05 | 2005-07-07 | Pharmexa A/S | Verfahren zur therapeutischen impfung |
| DE10042598A1 (de) * | 2000-08-30 | 2002-03-28 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| WO2003026581A2 (en) * | 2001-09-26 | 2003-04-03 | Intermune, Inc. | Pharmaceutical compositions and methods for treating cancer |
| JP4764165B2 (ja) * | 2002-11-06 | 2011-08-31 | サイクラセル リミテッド | ドセタキセル及びｃｄｋ阻害剤を含む組合せ |
| CA2510309C (en) * | 2002-12-16 | 2014-09-16 | Liyange P. Perera | Recombinant vaccine viruses expressing il-15 and methods of using the same |
| CN1511549A (zh) * | 2002-12-27 | 2004-07-14 | 张小丽 | 含有黄芩的抗肿瘤、抗炎症及肿瘤预防药物的组合物 |
| ITMI20030317A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale. |
| US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| EP1628531A4 (en) * | 2003-05-16 | 2010-06-30 | Idera Pharmaceuticals Inc | SYNERGISTIC TREATMENT OF CANCER BY COMMON USE OF IMMUNOMER AND CHEMOTHERAPEUTICS |
| DE602004020769D1 (de) * | 2003-06-25 | 2009-06-04 | Bn Immunotherapeutics Inc | Aufreinigung von her-2-varianten |
| KR20060033870A (ko) | 2003-06-25 | 2006-04-20 | 파멕사 에이/에스 | Ｈｅｒ-2 변이체의 정제 |
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| HUE030037T2 (en) * | 2005-02-23 | 2017-04-28 | Bavarian Nordic As | Use of modified anemic virus for rapid induction of immunity against gluten virus or other agents |
| NZ575388A (en) | 2006-10-06 | 2012-03-30 | Bn Immunotherapeutics Inc | Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer |
-
2007
- 2007-10-05 NZ NZ575388A patent/NZ575388A/en unknown
- 2007-10-05 US US11/905,876 patent/US7807146B2/en active Active
- 2007-10-05 ES ES07839307.1T patent/ES2500465T3/es active Active
- 2007-10-05 CA CA2665068A patent/CA2665068C/en active Active
- 2007-10-05 NZ NZ597998A patent/NZ597998A/xx unknown
- 2007-10-05 EP EP13154196.3A patent/EP2596801B1/en active Active
- 2007-10-05 DK DK13154196.3T patent/DK2596801T3/en active
- 2007-10-05 WO PCT/US2007/021436 patent/WO2008045346A2/en not_active Ceased
- 2007-10-05 JP JP2009531472A patent/JP5964540B2/ja active Active
- 2007-10-05 DK DK07839307.1T patent/DK2073837T3/da active
- 2007-10-05 EP EP07839307.1A patent/EP2073837B1/en active Active
- 2007-10-05 PT PT78393071T patent/PT2073837E/pt unknown
- 2007-10-05 AU AU2007307080A patent/AU2007307080B2/en active Active
-
2009
- 2009-03-17 IL IL197633A patent/IL197633A/en active IP Right Grant
-
2010
- 2010-08-31 US US12/872,156 patent/US8313740B2/en active Active
-
2014
- 2014-03-11 JP JP2014047741A patent/JP6124822B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2665068C (en) | 2016-01-05 |
| JP2010505850A (ja) | 2010-02-25 |
| US8313740B2 (en) | 2012-11-20 |
| JP5964540B2 (ja) | 2016-08-03 |
| EP2073837B1 (en) | 2014-06-25 |
| WO2008045346A3 (en) | 2009-06-04 |
| NZ597998A (en) | 2013-08-30 |
| CA2665068A1 (en) | 2008-04-17 |
| IL197633A0 (en) | 2011-08-01 |
| PT2073837E (pt) | 2014-09-22 |
| JP2014129416A (ja) | 2014-07-10 |
| NZ575388A (en) | 2012-03-30 |
| US20110008294A1 (en) | 2011-01-13 |
| WO2008045346A2 (en) | 2008-04-17 |
| EP2596801A1 (en) | 2013-05-29 |
| US20080213302A1 (en) | 2008-09-04 |
| DK2596801T3 (en) | 2018-08-13 |
| EP2073837A2 (en) | 2009-07-01 |
| EP2596801B1 (en) | 2018-05-02 |
| AU2007307080A1 (en) | 2008-04-17 |
| DK2073837T3 (da) | 2014-09-29 |
| JP6124822B2 (ja) | 2017-05-10 |
| US7807146B2 (en) | 2010-10-05 |
| ES2500465T3 (es) | 2014-09-30 |
| AU2007307080B2 (en) | 2014-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL197633A (en) | A combination of mva and taxane for the treatment of cancer with overexpression of her – 2 | |
| IL248204A0 (en) | Combined treatment of tumors expressing 38cd | |
| GB0700560D0 (en) | Device and method for the treatment of diseased tissue such as tumours | |
| PT2340042E (pt) | Métodos e composições para o tratamento de cancro | |
| SI2200431T1 (sl) | Sestave in metode za zdravljenje raka | |
| EP2049151A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| IL210810A0 (en) | Compositions for the treatment of pain and/or inflamtion | |
| IL197315A0 (en) | Treatment of cancer | |
| ZA200904492B (en) | Compositions and methods for the treatment of infections and tumors | |
| EP2049139A4 (en) | TREATMENT OF TUMORS EXPRESSING RAS | |
| PT2101731T (pt) | Endoxifeno para utilização no tratamento de cancro | |
| IL196843A0 (en) | Compositions and methods for the treatment of radiation proctosigmoitis | |
| ZA201003425B (en) | 5-cyano-thienopyridines for the treatment of tumors | |
| WO2007081751A9 (en) | Compositions and methods for the treatment of cancer | |
| EP2176406A4 (en) | COMPOSITIONS AND METHOD FOR CANCER TREATMENT | |
| EP2144887A4 (en) | PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER | |
| GB0604471D0 (en) | Device and method for the treatment of tumours | |
| PL2331092T3 (pl) | Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu | |
| IL200966A0 (en) | Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer | |
| SG169378A1 (en) | Benzoisoindole derivatives for the treatment of pain | |
| IL226363A0 (en) | Compounds and methods for treating cancer | |
| GB0517387D0 (en) | Combinations for the treatment of cancer | |
| IL205339A0 (en) | Compounds and methods for the treatment of cancer | |
| GB0600903D0 (en) | Treatment of cancer | |
| GB0604114D0 (en) | Combinations for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |